Anthony Romero, Ph.D.
Director, Medicinal Chemistry
Dr. Romero joined Terns in 2018. Prior to Terns, he was a Director of Chemistry at Unity Biotechnology, where he lead the development of novel senolytic molecules for the treatment of diseases of aging. Before joining Unity, Dr. Romero was a chemistry lead on epigenetic and inhalation programs at Genentech, where his work contributed to the discovery of GNE-781. During his tenure at Genentech, Dr. Romero also helped to lead the implementation of fragment-based lead discovery (FBLD). Dr. Romero started his career at Merck focused on diabetes and thrombosis research and he is a co-inventor of the AMPK inhibitors MK-3903 and MK-8722.
Dr. Romero is a graduate of Occidental College (A.B., Chemistry) and the University of Kansas (Ph.D., Medicinal Chemistry). He was awarded an American Cancer Society postdoctoral fellowship to conduct chemistry research under Professor Dale Boger at The Scripps Research Institute.